Dr Amol Akhade (@suyogcancer) 's Twitter Profile
Dr Amol Akhade

@suyogcancer

Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists

ID: 1135941148378247168

linkhttp://suyogcancerclincs.com calendar_today04-06-2019 16:07:29

6,6K Tweet

3,3K Followers

125 Following

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo
Dr Amol Akhade
@suyogcancer

4 months ago

Tarlatamab. Anti -DLL3 BiTE got accelerated approval for extensive stage SCLC . Based upon Delphi-301 study , phase 2 . Approved dose is 1 mg on cycle 1 day 1 and 10 mg on cycle 1 day 8 and 15 and then every 2 weekly . Time to BiTE SCLC #LCSM U.S. FDA IASLC

Tarlatamab. Anti -DLL3 BiTE got accelerated approval for extensive stage SCLC . Based upon Delphi-301 study , phase 2 . Approved dose is 1 mg on cycle 1 day 1 and 10 mg on cycle 1 day 8 and 15 and then every 2 weekly . Time to BiTE SCLC #LCSM <a href="/US_FDA/">U.S. FDA</a> <a href="/IASLC/">IASLC</a>